Roche (ROG) PT Set at CHF 260 by UBS Group

UBS Group set a CHF 260 price objective on Roche (VTX:ROG) in a report issued on Monday morning, www.boersen-zeitung.de reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

Several other research analysts also recently issued reports on ROG. Goldman Sachs Group set a CHF 325 price target on Roche and gave the stock a buy rating in a research note on Monday, September 11th. Kepler Capital Markets set a CHF 230 price target on Roche and gave the stock a neutral rating in a research note on Monday, September 11th. Credit Suisse Group set a CHF 300 price target on Roche and gave the stock a buy rating in a research note on Monday, September 11th. Deutsche Bank set a CHF 255 price target on Roche and gave the stock a neutral rating in a research note on Monday, September 11th. Finally, JPMorgan Chase & Co. reaffirmed a buy rating on shares of Roche in a research note on Monday, September 11th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of Hold and an average price target of CHF 263.42.

Roche (VTX:ROG) opened at CHF 244.50 on Monday. The stock has a market capitalization of $210,940.00 and a price-to-earnings ratio of 21.73. Roche has a one year low of CHF 226.10 and a one year high of CHF 273.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/01/12/roche-rog-pt-set-at-chf-260-by-ubs-group.html.

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply